RESVO

Japanese

ABOUT USRESVO members

Arata Oh-nishi
CEO&CTO PhD. He found FLC as biomarker and new drug targets. Research Professor of Shimane Univercity
2020 Appointed CEO & CTO
RESVO Founding Member
Masatoshi Shimura
CFOExperienced entrepreneurship as a student. He has been in his current position since 2018 after gaining experience in management at major control equipment and chemical manufacturers.

ADVISER

Mori Ichiro
Drug discovery advisor
After working at Novartis, GSK, and Pfizer, he is currently a professor at the Graduate School of Science, Technology and Innovation, Kobe University.

COMPANY

For people suffering from mental illness

According to estimates by the Ministry of Health, Labor and Welfare, Japan's economic loss due to mental illness now amounts to 2.7 trillion yen per year. Even from this figure, it can be seen that many people are currently suffering from mental illness. In addition, the financial and social burden on the person who developed the disease is large, and it is important to detect signs of mental illness early and link them to appropriate care. Therefore, we would like to use our research and technology to create a foothold for early diagnosis and treatment of people suffering from mental illness.

Company
RESVO, INC.
CEO & CTO
Arata Oh-Nishi Ph.D.
Establishment
January 23 2015
Head Office
4th floor, Frontier Building,
11-2 Ekimaehoncho,Kawasaki-ku kawasaki-shi,
Kanagawa 210-0007 Japan
Capital
58.18 million yen(Capital reserve not included)
Business content
  • R&D on mental illness and Stress related. Joint research and contract inspection business in the above areas.
CONTACT

Contact

For more information on our business and research contents, please visit our website. Please feel free to contact us.

Contact Us